

Testimony of H. Westley Clark, MD, JD, MPH
Dean's Executive Professor of Public Health
Santa Clara University
Santa Clara, California

**Before the Health Subcommittee
of the House Energy and Commerce Committee
May 8, 2018**

My name is Dr. H. Westley Clark. I am a psychiatrist, addiction medicine specialist and a professor. I retired from Federal service after providing clinical care to our nation's veterans for 14 years and after directing the Center for Substance Abuse Treatment in the Substance Abuse and Mental Health Services Administration for 16 years.

I am currently teaching undergraduates about substances of misuse to undergraduates at Santa Clara University, recognizing that the young men and women of this Nation are both at risk for substance misuse and have the potential to changing the cultural dynamic which puts their age cohort at greatest risk for misuse and overdose.

I am here to advocate for maintaining the integrity of 42 USC 290dd-2 and to keeping those federal regulations that protect individuals with substance use disorders who would be discouraged from seeking substance use disorder treatment, because they would be subject to discrimination and legal consequences in the event that their information is improperly used or disclosed.

There are two contemporary phenomenon that I would cite as a prelude to the substance of my testimony: (1) the Facebook/Cambridge Analytica issue, and (2) the NIH All of Us longitudinal research project.

Without venturing into the web of politics associated with the Facebook/Cambridge Analytica issue, it was clear from the general discourse and dialogue about the misuse of information that surfaced from that chain of events, that privacy and confidentiality were important to people, that their sensitive information disclosed without their consent represented a violation of autonomy and sense of self. It was also clear that those violated were not happy about the situation.

That the information was subsequently used for predictive analytics, according to media accounts, for the purpose of influencing those whose information had been compromised showed the potential for abuse. Keep in mind that this was not a case of data security, but a case of breach of confidentiality and apparent invasion of privacy.

I turn next to the NIH All of Us protocol. The NIH is seeking 1 million people to volunteer for an ambitious study that will last 10 or more years. The objective of this study is to build a research resource composed of participant-provided information (PPI), including environmental, physiologic, and health data and biospecimens from 1 million or more research participants.

The NIH Study will include all data available in the participants Electronic Health Records, including demographics, visits, diagnoses, procedures, medications, laboratory visits, vital signs, and physician notes. In addition, the NIH notes that the pertinent information may include data about mental health, substance use, or HIV status.

However, what is interesting about the All of Us Study protocol and relevant to this hearing is that participants will be given the option of providing consent to release information from their electronic health records. In other words, patients will be asked to consent to the use of data from their EHRs. While this is a research protocol and falls under the aegis of research consent and disclosure, the fact remains that consent is a requirement and that the right to refuse consent is respected. The fact that the All of Us study anticipates using additional data from Social Security Death Master Files, pharmacy system data, and health registry data makes consent all the more important, as aspects of study participants health lives will be examined. This research will also provide information about the willingness of participants to consent to have their electronic health information used. Furthermore, formal consent is required because academic scientists, commercial organizations, and interested citizen scientists will be able to request access to the participants' data; thus, the array of inquiring entities will not be given automatic access to this data.

The All of Us protocol invokes the idea of the comprehensive health record heralded by some EHR vendors who seek a new generation of electronic information about people, information that includes social determinants, about what people eat, how much they sleep, if they are obese or live in a food desert, or whether they are lonely.ⁱ Thus, the medical record becomes a comprehensive dossier on the individual ripe for use or misuse. The hope, of course, is that in coming decades adequate resources will be available to address the convergence of social determinants and health. In the meantime, it has yet to be determined that the necessary linkages and interoperabilities can be fostered to actually benefit the patient rather than simply integrating all that is known about an individual using the health record as the portal.

Privacy, confidentiality, and the consent are important to Americans, and something that should be respected. If the two vignettes I've used to introduce my testimony can be understood in the context of the current discussion, then you, as members of Congress, will understand the importance of maintaining the protections of 42 USC 290dd-2 and 42 CFR part 2 to a population that is more vulnerable than those on Facebook or those who agree to participate in the All of Us Study.

As you well know, we are in the midst of the worse opioid epidemic that this nation has ever seen. And, at the same time, less than 10% of people who need treatment seek treatment. Instead of recognizing that we need to reassure those in need of treatment that they can trust the

treatment community to use the information they disclose, many are calling for severely weakening 42 USC 290dd-2 and 42 CFR Part 2..

It is argued that the opioid epidemic justifies modifying 42 CFR Part 2 to address the opioid overdose deaths and the misuse of opioids. While the issue of opioid misuse is of major importance, we should keep in mind that 42 CFR Part 2 does not just apply to opioids.

Data from the National Survey on Drug Use and Health reveals that 65 million Americans 12 and Older admit to binge drinking in the past month. Of these, 16 million admit to being heavy drinkers. We should also be aware that 24 million people admit to being past month users of marijuana. ⁱⁱ

These numbers alone suggest the magnitude of the issues we are confronting today, as they exceed the 3.4 million people who admit to past month use of pain relievers and the 475,000 who admit to past month users of heroin.

The critical question today is how do we get the 28.6 million Americans who are current illegal drug users and the 65 million people who are binge drinkers to discuss their substance use with the medical community?

“[W]hat should we do about the opioid crisis? First, we must be realistic about who is getting in trouble with opioid pain medications. Contrary to popular belief, it is rarely the people for whom they are prescribed. Most lives do not come undone, let alone end in overdose, after analgesia for a broken leg or a trip to the dentist. There is a subset of patients who are vulnerable to abusing their medication—those with substance use histories or with mental health problems. Ideally, they should inform physicians of their history, and, in turn, their doctors should elicit such information from them.”ⁱⁱⁱ

Although the use of alcohol is legal for those over the age of 21, the medical community should also communicate with their patients about alcohol use. However, as for all psychoactive substances, communications between clinician and patient require trust. Trust is not possible if the function of disclosure is the release of sensitive information into a virtual data storm sewer

It is often argued that substance use should be treated like HIV, the flu, diabetes or hypertension and therefore should be treated like those conditions. Those who make this argument blind themselves to the reality that many substances of misuse are illegal, and that disclosure of such information can give rise to harm to the individual affected.

The harms to which a person who admits to substance use may suffer includes the loss of employment, the loss of housing, the loss of child custody, the loss of benefits, stigma and discrimination, the loss of privacy and the loss of autonomy.^{iv} Medical records can also be used to incriminate a person and subject that person arrest, prosecution, and incarceration.

It is irresponsible to ignore the real harms to which a person with a history of substance use could be subject. It is also irresponsible to ignore the implication that modern electronic health information has for privacy and confidentiality. It is sometimes said that computers have eidetic

memories----they don't forget. Thus, people in recovery from alcohol and drug use who have long since stopped using are still at risk for discrimination and stigma.

The case is often made that the health care delivery systems need to know about the substance use history of a patient. You don't hear why providers can't simply ask patients themselves about their substance use histories. You hear that it is too confusing for clinicians to know about 42 CFR Part 2 and to apply the rules. Yet, these same clinicians and health care systems spend quite a bit of time learning about and executing reimbursement rules, licensing rules, administrative rules, quality standard rules, and all the other rules that are necessary to get paid for the services delivered to the very people whose agency and dignity are now deemed too inconvenient to respect..

Furthermore, there are those in the health care delivery system, including those involved with insurance and reimbursement who are looking for data to inform predictive analytics to anticipate those might be at risk for substance use disorders in order to actuarially determine what course of prospective action should be taken to address those with such possibilities.

Just last week, the USA Today ran a front page article on the evolving image of marijuana, noting that 24 million Americans said that they used marijuana in the past 30 days, 90% for so-called recreational purposes and 10% for medical reasons.^v Clearly, clinicians should want to know why the estimated 2.4 million medical marijuana users choose to use that psychoactive substance to cope with their medical problems. Yet, even though, an estimated 30 states recognize some form of medical marijuana, it remains a Schedule I drug and, thus, not legal under the federal Controlled Substances Act. While marijuana does not carry the morbidity and mortality profile of the opioids, we should want patients to willingly disclose their use of this substance to their health care providers without fear of social or legal repercussions.

I rarely hear or read about concern about the harm to the patient. Instead, I hear concern for the convenience of the delivery system, a concern that creates an adversarial relationship between patient and practitioner rather than respect for and trust from the patient. What appears to underlie the argument for administrative efficiency and systems needs is distrust of the patient, if not contempt for the patient.

Now is the time to welcome people with substance use disorders into the health care delivery system, not with the demand that such individuals concede their agency, dignity and privacy to the administrative convenience of the health care delivery system, but with the old adage of "First, do no harm."

Distrust and Contempt for people with substance use disorders has led to distortions and misinterpretation of 42 CFR Part 2. Emergency room clinicians argue that a patient with an opioid use disorder comes into the ED following an overdose and is unresponsive, 42 CFR part 2 keeps them from getting lifesaving information. Not true, 42 CFR Part 2 allows those emergency room clinicians to access Part 2 protected information kept either by a health information exchange or a substance use disorder treatment program in order to treat the patient in the emergency status.

Internists may argue that it is critical not to prescribe an opioid to an opioid dependent patient who is on methadone. However, they don't establish that asking the patient about their methadone treatment is ineffective. Furthermore, they don't establish that checking the PDMP is ineffective. If the PDMP is ineffective, they don't argue for improving PDMPs by making them real time and regional.

Family members, concerned about the welfare of their opioid dependent adult relatives, are not precluded from getting information when an unconscious adult is brought into the ER following an opioid overdose. Emergency room clinicians under this situation are not prohibited from sharing information with those concerned family members.

It is argued that 42 CFR Part 2 perpetuates the stigma of addiction. This disingenuous argument ignores the laws, regulations, policies and social view about addiction and substance use disorders. It is not illegal to be depressed. It is not illegal to have diabetes. It is not illegal to have a broken leg. It is illegal to use heroin. It is illegal to use marijuana. People with untreated or active diabetes are protected by the Americans with Disabilities Act. People with untreated or active substance use are not. There are no signs posted at the employment office of employers declaring that the workplace is a hypertension free workplace and that all new applicants will have their blood pressure checked; there are no signs saying that anyone with evidence of hypertension shall be denied employment.

The Department of Health and Human Services has already moved to accommodate the modernization of 42 CFR Part 2 through two rounds of rulemaking, including a 2017 Final Rule and a 2018 Final Rule. However, the EHR community and a number of health systems remain restless, impatient and intolerant of those with substance use disorders, suggesting that information sharing is more important than the people about whom that information is shared. Thus, the regulatory efforts to allow patient to provide a general disclosure for substance use disorder information, to offer some flexibility in transmitting substance use data electronically, and to clarify the circumstances in which providers can disclose patient information to contractors and subcontractors for payment and healthcare operations is not enough. The critics of 42 CFR seek to expose those with substance use disorders who seek treatment, making the exercise of treatment a dangerous proposition.

Patient Attitudes toward Treatment

We spend millions of dollars collecting information about the substance use patterns of people in the US. Perhaps we should be concerned about the reality that 89% of people, who meet criteria for needing substance use disorder treatment, did not receive such treatment.^{vi}

Of the 28.6 million people who misused illicit drugs and the 65 million people who were binge drinkers in the past month, only 3.8 million people received treatment in the past year. Of course, mere use does not equate with dependence or needing treatment. However, NSDUH data indicate that over 20 million people 12 or older met criteria for a substance use disorder in the past year in 2016, with 2.1 million meeting criteria for an opioid use disorder.

What is equally interesting is that of the people who met criteria for needing treatment and did not receive treatment, 95.5% perceived no need for treatment. In short, 18.7 million people needed but did not receive treatment; of these, 17.9 million perceived no need for treatment.

Now comes the critics of 42 CFR Part 2, under the flag of bringing integrated treatment to those in need, claiming that it is 42 CFR Part 2 that operates as a barrier to effective and efficient treatment of opioid use disorders, claiming that there is no need for special concerns about substance use disorders, today, never mentioning how they will explain to those actually seeking treatment and those in need of treatment the ramifications of attenuating 42 CFR Part 2.

Changing 42 CFR Part 2 and the Response of Substance Users

It is important to recognize that 42 CFR Part 2 does not apply to most clinicians or most clinical settings. In fact, 42 CFR Part 2 only applies to programs that hold themselves out “as providing, and provides, alcohol or drug abuse diagnosis treatment, referral for treatment or prevention.” Of course, 42 CFR Part 2 governs substance use disorder patient records for those patients who receive, diagnosis, referral or treatment from (a) an identified unit of a general medical facility that holds itself out as providing, and provides alcohol or drug use disorder diagnosis, treatment or referral for treatment or (b) medical personnel or other staff in the general medical care facility whose primary function is to provide those services.

So, it is the patient records of a substance use disorder program (which includes the substance use patient records clinicians who hold themselves out as treating people with substance use disorders in even in non-specialty settings), that are controlled by 42 CFR Part 2. This creates a responsibility for the substance use disorder program to explain to the patient the meaning of confidentiality as it applies to information disclosed to the treatment program.

For the millions of people whose substance use does not meet criteria for protection under 42 CFR Part 2, HIPAA may control. However, HIPAA only controls those health care providers, such a doctors, clinics, psychologists, dentists, chiropractors, nursing homes, or pharmacists that transmit any information in an electronic form in connection with a transaction for which DHHS has adopted a standard. HIPAA’s covered entity standard also applies to health plans and health care clearinghouses. As broad as this covered entity standard is, it does not cover the substance use disorder treatment landscape.

Those seeking changes in 42 USC §290-dd may be attempting to reshape the SUD treatment landscape and to increase the medicalization of SUD treatment. According to data collected by the Substance Abuse and Mental Health Services Administration, private non-profit organizations operated 53 percent of all facilities in its data base and were treating 49 percent of all clients; in addition, private for-profit organizations operated 35 percent of all facilities and were treating 39 percent of all clients. While the focus on opioids is indeed important, the reality is that opioids are not the primary substance treated by SUD treatment facilities. The medium number of clients treated

by non-opioid treating programs in 2016 was 34. In fact, looking at *Opioid treatment programs* certified by SAMHSA for the provision of medication-assisted therapy with methadone and/or buprenorphine, only 8 to 9 percent of all facilities between 2006 and 2016 fit this category. Nevertheless, it is true that the proportion of all clients receiving methadone from any of the over 14,000 programs in the SAMHSA data base ranged from 23% to 30% in period 2006 to 2016; a large minority of patients in SUD treatment, but still a minority of patients.

The dominant forms of therapy provided in SUD treatment are behavioral, not medication oriented. Such treatments as generic substance abuse counseling, relapse prevention, cognitive behavioral therapy, motivational interviewing, anger management, trauma related counseling, 12-step facilitation, dialectical behavioral therapy, rational emotive therapy and other behavioral interventions are the norm.

Furthermore, while 89 percent of the over 14,000 SUD facilities accepted cash or self-payment, only 68% accepted private health insurance, 62% accepted Medicaid and only 34% accepted Medicare. However, with the advent of the Patient Protection and Affordable Care Act and parity laws, there is a push to increase reimbursement opportunities by some. Thus, eliminating the protections of 42 CFR part 2 from current spectrum of SUD treatment facilities, larger, more technology savvy treatment programs would be able to exert greater influence in the SUD treatment market, consolidate business practices and decrease competition. Whether better care would be enhanced is a matter for time to tell. Whether costs would actually rise over time with decreased completion would also be a matter for observation. The ethical question remains, should the privacy of the vulnerable be sacrificed in the service of market dynamics?

We must keep in mind that that HIPAA regulations allow for unconsented disclosure of patient information for, among other things, healthcare operations.

Healthcare operations include:

- Underwriting, enrollment, premium rating, and other activities related to the creation, renewal, or replacement of a contract of health insurance or health benefits, and ceding, securing, or placing a contract for reinsurance of risk relating to claims for health care (including stop-loss insurance and excess of loss insurance)
- Reviewing the competence or qualifications of health care professionals, evaluating practitioner and provider performance, health plan performance, conducting training programs in which students, trainees, or practitioners in areas of health care learn under supervision to practice or improve their skills as health care providers, training of non-health care professionals, accreditation, certification, licensing, or credentialing activities;
- Business planning and development, such as conducting cost-management and planning-related analyses related to managing and operating the entity, including formulary development and administration, development or improvement of methods of payment or coverage policies

- Business management and general administrative activities of the entity, including, but not limited to:
 - (i) Management activities relating to implementation of and compliance with the requirements of this subchapter;
 - (ii) Customer service, including the provision of data analyses for policy holders, plan sponsors, or other customers, provided that protected health information is not disclosed to such policy holder, plan sponsor, or customer.
 - (iii) Resolution of internal grievances;
 - (iv) The sale, transfer, merger, or consolidation of all or part of the covered entity with another covered entity, or an entity that following such activity will become a covered entity and due diligence related to such activity; and
 - (v) Consistent with the applicable requirements of § 164.514, creating de-identified health information or a limited data set, and fundraising for the benefit of the covered entity.

Do non-42 CFR Part 2 covered providers explain the width and depth of the health care operations provision under HIPAA? Would patients exempted from 42 CFR Part 2 protections feel that disclosing histories of substance use is wise under HIPAA, even if experimental or rare use of psychoactive substances is involved? Would a patient experiencing a co-occurring disorder of trust and substance use feel comforted knowing that her personal information could be disclosed to the broad spectrum of entities covered under the healthcare operations rubric, especially in small communities? Much of the literature favoring weakening 42 CFR Part 2 or aligning it much more substantively does not discuss this perspective. Ignoring the autonomy of the patient seems to be the prevalent view, diminishing the identity and integrity of the patient is the net effect.

We can learn a lot about the use and misuse of private information from the Facebook/Analytica problem . There, from 50 to 87 million people reportedly had their private data used for political and financial gain without their knowledge or consent. While the spiral of events started out apparently innocently enough, the proprietary interests in predictive analytics apparently overcame whatever promises and safeguards in place. Given the spectrum of exceptions that are inherent in HIPAA's hospital operations category and given the interest of electronic health record vendors and data brokers in predictive analytics, I believe that HIPAA is an inadequate safeguard for those seeking substance use disorder treatment. .

Moving from HIPAA into those programs whose records are controlled by 42 CFR Part 2, it is clear that those with moderate to severe substance use disorders requiring treatment already do not believe that treatment is warranted. How are we going to encourage them to participate in treatment when we propose to broadcast their personal information through networks of uncertainty entities with uncertain purpose?

Unfortunately, there are more serious consequences to voiding the patient's right to consent to the disclosure of sensitive information. The unconsented disclosure of sensitive information

resulting in harm to the patient could easily give rise to suicide, relapse to substance use or overdose; these are tragic events that we should be avoiding rather than pretending that the agency and dignity of the patient have no value and can be compromised for the convenience of EHR vendors, data miners and health care operations. Furthermore, we should recognize that many in substance use disorder treatment are at risk for depression, anxiety and other psychiatric disorders, any of which would be made worse by a breach of trust by substance use disorder treatment programs and the health care delivery system.

The loss of privacy due to unconsented disclosure itself is a harm, perhaps not of the magnitude of the loss of a job or of child custody, but a harm nevertheless. Patients have a legitimate liberty interest in their autonomy, in the right to make decisions about their lives.

Blaming the Vulnerable

The Health Information Technology for Economic and Clinical Health Act (HITECH Act) was enacted under Title XIII of the American Recovery and Reinvestment Act of 2009^{vii}. It provided billions of dollars of incentives to an array of primary care hospitals and to physicians to adopt electronic health records and to promote the exchange of health information. However, that same act essentially ignored the behavioral health community; as a result, there were no incentives available for substance use disorder treatment programs to adopt electronic health records. In addition, there were no incentives to the electronic health record industry to develop software and protocols specific to the behavioral health community and the sensitive information generated by behavioral health providers, information of little use to most primary care providers.

At the time of the unfolding of the HITECH Act, I was the Health Information Technology Strategic Initiative Lead for SAMHSA. My team and I met with a number of software vendors in an effort to address the unique needs of the behavioral health community and to compensate for the omission of behavioral health from the promulgated incentives provided to general medicine. We met with little success.

In order to compensate for excluding behavior health from the incentives, standards, and designs for the evolving EHR systems, information exchanges, and the growing recognition that comprehensive health care required addressing behavioral health, efforts were mounted to promote the fiction that behavioral health patient information contained nothing unique and distinct from the general health care environment.

The notion that all health care information is equivalent runs counter to the historical status recognized in the psychotherapist-patient privilege which was justified on the grounds that some personal health information was more sensitive than others. Discussions of mental health, substance use, and sexual health are inhibited unless the patient has certain reassurances that highly sensitive personal health information would remain between themselves and their health care providers. Indeed, “the prevailing legal default and ethical norm in Western nations both

strongly favor the preservation of patient confidence in the absence of compelling grounds to act otherwise.”^{viii}

As Shenoy and Appel point out, the behavioral health record “often combines data related to the patient’s present symptoms, with a descriptive narrative of the patient’s life experience, including sensitive details of psychological trauma, domestic violence, incarceration, sexual encounters, and substance abuse. Much of this information is of great value to a therapist, but not always of clinical use to many other medical providers. The stigma attached to mental healthcare among some individuals and in certain cultural communities even leads some patients to avoid using their insurance for psychiatric care in order to protect their privacy.”^{ix}

While I was at SAMHSA, we recognized the continued sensitivity of behavioral health information, especially for substance use in particular. As a result, we developed an open source code base through a contract that would provide an inexpensive software application for the behavioral health community.^x Unfortunately, due to complaints of unfair competition we discontinued our efforts.

The HITECH Act with its focus on meaningful use and information exchange did not change the unique character of behavioral health information. As a result, we developed Consent2Share, an open-source data segmentation platform that could be incorporated into existing electronic health records to allow patients to be able to consent to the disclosure of highly sensitive patient information.^{xi}

Consent2Share was developed evolved within the Data Segmentation for Privacy (DS4P) initiative within ONC’s Standards and Interoperability (S&I) Framework to improve the interoperability of the plethora of EHRs containing sensitive information that must be protected. The DS4P initiative met its two goals, which were to: Demonstrate how standards can be used to support current privacy policies, including 42 CFR Part 2, for sharing sensitive health information across organizational boundaries; and develop standards that will enable sensitive electronic health information to flow more freely to authorized users while improving the ability of health IT systems to implement current privacy protection requirements for certain Types of health care data, such as substance use disorder patient records.

Unfortunately, the EHR vendor community felt no need to support data segmentation, dismissing the importance of privacy and confidentiality to patients. Furthermore, health information exchanges chose to ignore the importance of privacy and confidentiality to the patients by choosing not to embrace the utility of data segmentation and patient choice. Naturally, without data segmentation and consent management capacities, substance abuse treatment programs operating under 42 CFR Part 2 requirements have diminished capacities to share information with integrated treatment models that ignore patient choice.

In short, SAMHSA was able to demonstrate that patient choice could be respected without compromising the agility and flexibility of required for integrated information exchange.

However, for matters of mere convenience and low market demand, most EHR vendors and health information exchanges chose to support the less expensive and ethically problematic position of eviscerating 42 CFR Part 2..

Economic Disparities, HIPAA, and Confidentiality

What is remarkable about the industry and provider objections to having patients weigh in on whether their private medical information should be disclosed is the loophole in HIPAA that allows rich people or middle income people to have the right to restrict certain disclosures of protected health information to a health plan where the individual pays out of pocket in full for the health care or service received^{xii}. Health care providers, under HIPAA, are required to include such a statement in the notice of privacy practices provided to the patient. Thus, if a patient is rich and can pay for their own treatment in full, including substance use disorder treatment or if they are middle class and can mortgage their home to pay for their treatment in full, they can avoid disclosing the fact that they are in substance use disorder treatment to their health plan. What is amazing is that providers who are committed to doing no harm are willing to sacrifice poor whites, poor blacks, poor Hispanics, poor Native Americans, poor Alaskan Natives, poor Hawaiians, and poor Asians in the service of a fiction of needing highly sensitive personal information without a patient's consent when they could most likely receive that information simply by asking the patient. In situations where a patient refuses consent to disclose sensitive information to entities outside of the treatment situation, that should be the patient's prerogative.

Given the well documented harm that can happen to a person who is an admitted substance users, it should not be EHR vendors or health systems or substance use disorder treatment providers that should decide what sensitive information should be disclosed outside of a substance use treatment process. Financial ability should not be the deciding factor on whether a person retains a modicum of control over their personal information.

Increased Liability for Substance Use Disorder Treatment Programs

Substance Use Disorder treatment programs have a duty to inform patients about the limits of confidentiality. Given the spectrum of entities under the rubric of healthcare operations, it would be difficult for a substance use disorder treatment program to accomplish this with any degree of effectiveness; this would expose the covered program to liability.

Given that the potential harms from inappropriate disclosure of sensitive information garnered during substance use disorder treatment is real, the disclosure of that information may give rise to legal claims including lawsuits for some form of negligence. Unfortunately, since substance abuse treatment programs will be the entities releasing information under the proposed modified 42 CFR Part 2, undoubtedly they will bear the brunt of the legal burden. Increased liability insurance, legal costs, and impaired reputations will ensue. After all, once sensitive information is released into the entity that releases that information has no control over its distribution. The

question would become should substance abuse treatment program that released the information have known that it contained information that could be used to the detriment of their current or past patient.

Substance use disorder treatment programs caught up in lawsuits may have to withdraw from the treatment marketplace. Treatment programs that close under the weight of malpractice claims will only diminish the number of available treatment slots. The cost of care will also increase as treatment programs have to compensate for the increased administrative costs of doing business.

Conclusion:

We cannot adequately address the current opioid epidemic if we remove the protections that 42 cfr part 2 and its authorizing legislation, 42 USC § 290dd-2, offers. We cannot treat those experiencing substance use disorders with contempt by weakening the protections that they currently have. We cannot treat those who experience substance use disorders as a means to an ends, attempting to compensate for the lack of public investment in electronic health records for the behavioral health treatment communities following the HITECH Act's focus on primary care.

Efforts to balance the health information technology requirements of integrated systems while preserving a patient experiencing a substance use disorder's right to consent to the disclosure of their substance use treatment history and sensitive matters subsumed under that history have been thwarted by the EHR industry and by health information exchanges. The claim that it would cost too much is overshadowed by the existence of open source strategies that could accomplish the necessary consent management strategies and by the inherent right of a person to determine what happens to sensitive information.

We have contemporary examples of data misuse and data appropriation. The most immediate and germane is the Facebook/Cambridge Analytica experience. We also have an example of an effort to enlist the cooperation and consent of those who participate in efforts to personalize medicine and to collect data on willing participants in the All of Us NIH project; by respecting the consent of its participants, the NIH hopes to engage 1 million people for a longitudinal study. While the All of Us project may yield strategies to support a comprehensive health record on individuals, it is not clear whether the public will be willing to have comprehensive dossiers of their lives hanging in the electronic cloud for the use of those who gain access. The 10 year time line for this research should provide interested parties critical information about the acceptability of comprehensive health records and the utility of predictive analytics that uses information that goes beyond traditional health related data. However, it is premature to adopt such strategies, and certainly inappropriate to use vulnerable populations such as those with substance use disorders as the pilot target groups to vet such strategies.

Unlike the All of Us project, Congress is being asked to conduct a grand experiment, with those who present for substance use disorder treatment functioning as unwitting test subjects and with no suitable IRB or patient advocate. In this experiment, the presumption is that despite laws, regulations, customs and attitudes to the contrary, no harm will come to those currently protected by 42 USC 290dd-2 with its removal., The burden of this presumption falls not on those with assets and not on those with resources to negotiate, arbitrate or litigate, but on the vulnerable.

Congress is being asked to alter the substance use disorder treatment landscape to favor economic models of care that favor corporate entities over local entities, that benefit regional providers over local providers and that decrease competition rather than increasing competition. Again, by sacrificing the informational and decisional privacy of those with SUDs, aggressive market practices would be encouraged without having protected the very objects of those practices.

Thus, despite the chorus of EHR and data vendors, health systems administrators, SUD treatment providers and others who convince themselves that it is appropriate to impose unnecessary risks of harm on those with substance use disorders seeking treatment, Congress should not abandon the commitment to encourage those in need of treatment to seek treatment by stripping away the limited protections offered under 42 USC § 290dd-2.

ⁱ Bernie Monegain, “Epic CEO Judy Faulkner is standing behind switch from EHRs to 'CHRs””, HealthITNews, October 6, 2017, <http://www.healthcareitnews.com/news/epic-ceo-judy-faulkner-standing-behind-switch-ehrs-chrs>, accessed May 5, 2018

ⁱⁱ Source: SAMHSA, Center for Behavioral Health Statistics and Quality. National Survey on Drug Use and Health, 2016.

ⁱⁱⁱ Satel, Sally, “The Myth of the Roots of the Opioid Crisis”, Politico Magazine, February 21, 2018,,<https://www.politico.com/magazine/story/2018/02/21/the-myth-of-the-roots-of-the-opioid-crisis-217034>, accessed 02/24/2018

^{iv} Lopez, Karla & Reid, Deborah, “Discrimination Against Patients with Substance Use Disorder Remains Prevalent and Harmful: The Case for 42 CFR Part 2, “ Health Affairs Blog, April 113, 2017, DOI: 10.1377/hblog20170413.059618, accessed 02/25/2018

^v Hughes, Trevor, “The Evolving image of pot” USA Today, 05/03/2018, 36(162), Pages 1A and 2A

^{vi} Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2015 and 2016.

^{vii} The American Recovery and Reinvestment Act of 2009, Public Law 111-5).

^{viii} Shenoy, A and Appel, JM, “Safeguarding Confidentiality in Electronic Health Record”, Cambridge Quarterly of Healthcare Ethics (2017), 26, 337-341.

^{ix} Ibid

^x <http://www.feisystems.com/what-we-do/learn-about-wits/why-choose-wits-2/>

^{xi} Department of Health and Human Services: 42 CFR Part 2: Confidentiality of substance use disorder patient records; proposed rule. Federal Register 81:6988-7024, 2016.

^{xii} Department of Health and Human Services; 45 CFR Parts 160 and 164: Modifications to the HIPAA Privacy, Security, Enforcement, and Breach Notification Rules Under the Health Information Technology for Economic and Clinical Health Act and the Genetic Information Nondiscrimination Act; Other Modifications to the HIPAA Rules. Federal Register 78 (17: 5566-5702